3D bioprinting company Organovo has entered a multi-year research collaboration agreement with the American pharmaceutical company Merck & Co.
Under the agreement, Merck will have access to Organovo’s NovoGen Biotprinting Platform as well as the commercial exVive3D human liver tissue, which is able to provide data to aid in the prediction of liver tissue toxicity in preclinical drug programs.
Organovo has lately made headlines when collaborating with cosmetic company L’Oreal to develop 3D printed skin tissue for cosmetic products as well as prescription drugs. Further, the company announced another research breakthrough by presenting their first fully cellular 3D printed kidney tissue.
On April 17, 2015, Organovo (NYSE: ONVO) entered into a multi-year research collaboration agreement with Merck Sharp & Dohme Corp. (NYSE: MRK). The Agreement will give Merck access to Organovo’s commercial exVive3DTM Human Liver Tissue service, and will also involve a collaboration to develop multiple custom tissue models utilizing the Company’s proprietary NovoGen Bioprinting PlatformTM, for use in drug development.